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1. INTRODUCTION 
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1.1 Urinary tract anatomy 
The human urinary tract is a contiguous hollow-organ system and its primary function 
is to collect, transport, store, and export urine periodically and in a highly controlled manner. 
This way, the urinary tract ensures the removal of metabolic products and toxic wastes that 
collect in the kidneys. The constant urine flow in the upper urinary tract and the intermittent 
excretion from the lower urinary tract also plays an important part in cleansing the urinary tract, 
from microbes that might have already entered. Anatomically consisting of, from proximal to 
distal, of renal papillae, renal pelvis, ureters, bladder, and urethra, each component of the 
urinary tract has specific anatomic characteristics and performs critical functions (1) (Figure 1). 
 
 
 
Figure 1. Anatomy of the urinary tract 
Source from http://www.pharmatips.in/Articles/Human-Anatomy/Introduction-To-Anatomy-
Of-Urinary-System.aspx 
 
The upper urinary collecting system consists of renal papilla, into which each renal 
tubule-rich pyramid drains, and is considered as the first large structure of the upper collecting 
system. Renal papillae are individually curved by a minor calyx, and this in turn narrows into 
an infundibulum. Infundibuli vary in number, length, and diameter but connect to form either 
2 or 3 major calyces. These connections are termed upper, middle, and lower-pole calyces 
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depending on which pole of the kidney they channel into. The renal pelvis represents the 
connection of these major calyceal branches and it can vary greatly in size and location (1). 
 
The ureters are bilateral fibromuscular tubes that drain urine from the renal pelvis to the 
bladder. They mostly averge 22–30 cm in length and pass through the retroperitoneum. They 
arise behind the renal artery and vein at the ureteropelvic junction (UPJ), then they continue 
inferiorly along the anterior part of the psoas muscle. When the ureters enter the pelvic cavity 
they pass medially and cross in front of the common iliac artery. The ureters pierce the bladder 
wall obliquely at the ureterovesical junction or UVJ and travel in this direction for 1.5 to 2.0 
cm within the bladder wall to cease in the bladder lumen as ureteral orifices. Along the ureter 
there are three segments that are physiologically smaller in diameter: the ureteropelvic junction, 
the ureterovesical junction, and where the ureters cross the common iliac artery. These three 
areas are clinically important as they represent the most common sites where ureteral calculi 
become fastened, causing obstruction (1,2). 
 
The bladder is a hollow, distensible muscular organ that is tetrahedral when empty and 
ovoid when filled. It predominantly consists of smooth muscle and collagen and, to a much 
lesser degree, elastin (2,3). Its superior portion is marked by the urachus, which attaches the 
bladder apex to the anterior abdominal wall. In males the bladder lies between the rectum and 
pubic symphysis and in females, between the rectum and uterus/vagina. Another difference is 
that in males, the base of the bladder rests on the endopelvic fascia and the pelvic floor 
musculature, and the bladder neck is 3 to 4 cm behind the symphysis pubis where it is fastened 
by the endopelvic fasciae and the prostate. In this section, there is a layer of smooth muscle that 
surrounds the bladder neck and forms the involuntary internal-urethral sphincter. In females on 
the other hand the base of the bladder and urethra rest on the anterior wall of the vagina (Figure 
2). 
 
 
4 
 
Figure 2. Anatomy of the male and female urinary system from left to right 
Soure from http://anatomymedicalook.com/anatomy-of-a-womens-urinay-system/anatomy-of-
a-womens-urinay-system-anatomy-of-a-womens-urinay-system-kidney-location-in-women/ 
  
The internal-urethral sphincter is not as well developed in females (4).The urethra 
begins at the distal end of the internal-urethral sphincter and is in continuation with the bladder. 
In males the urethra is mostly between 13 and 20 cm in length and is divided into prostatic, 
membranous, and penile portions. The prostatic urethra is 3–4 cm in length and runs through 
the length of the prostate. The membranous urethra spans 2 to 2.5 cm and this portion of the 
urethra is entirely surrounded by striated muscle known as the external-urethral sphincter. The 
penile portion of the urethra is contained within the corpus spongiosum and extends on an 
average of 15-cm, it dilates slightly in the glans penis (fossa navicularis) and ends at the 
external-urethral meatus. The female urethra is 3.8 to 5.1 cm long and is remarkably shorter 
than the male one, and passes obliquely from the bladder neck to external-urethral meatus along 
the anterior vaginal wall. The distal two-thirds of the female urethra are surrounded by a slow-
twitch striated muscle termed the external-urethral sphincter (1,5) (Figure 3). 
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Figure 3. Anatomy of the female and male urinary tract with focus on urethra 
Source from http://anatomymedicalook.com/anatomy-of-a-womens-urinay-system/anatomy-
of-a-womens-urinay-system-female-urinary-tract-diagram-female-reproductive-and-urinary/ 
 
Although it is not a part of the urinary tract, the vagina plays an important role in the 
UTI pathogenesis. It is a fibromuscular organ lined by epithelial cells that extends from the 
opening of the labia minora (vestibule) to the uterus. The anterior wall is approximately 7.5 cm 
long and its posterior wall approximately 9 cm long. The anterior wall is in proximity to the 
bladder base superiorly and urethra inferiorly. Posteriorly, the vaginal wall is separated from 
the rectum by the recto-uterine pouch superiorly and by the Denonvillier’s fascia and the 
perineal body inferiorly. The inner parts of the vagina are covered by a non-keratinized, 
stratified, squamous epithelium. At the onset of puberty the vaginal epithelium thickens and 
accumulates glycogen. The muscular layers consist of smooth muscle found that exists in both 
a longitudinal and circular orientation (1,6). In a reproductive women the normal vagina is 
colonized by the lactobacilli which produce lactic acid, producing a low pH condition which is 
unfavorable for the growth and colonization by uropathogenic microbes. This establishes one 
of the major host defenses, as alterations in these defenses are considered a key factor to UTIs 
(7). 
 
1.2 Urinary tract infection 
Urinary tract infections can be defined as a condition in which bacteria are colonizing 
and multiplying within the urinary tract. Urinary tract infections (UTIs) occur as a result of the 
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interaction of bacterial virulence and host biologic and behavioral factors, as opposed to highly 
efficient host defense mechanisms. There are three possible routes whereby bacteria can invade 
and spread within the urinary tract, the ascending, hematogenous, and lymphatic pathways.  
Diagnosis requires demonstration of bacteriuria defined as the presence of ≥105 or more colony 
forming units (CFU) per ml of urine with symptoms. Exceptions to this include patients with 
pyogenic abscess of kidney or perinephric tissue, obstructed pyelonephrosis or bacterial 
prostatitis in whom the urine may be sterile (6,8). 
 
Bacteriuria is a term that is used quite often and means, occurrence of bacteria in urine, 
while significant bacteriuria relates to the numbers of bacteria in voided urine that usually 
exceed the numbers caused by contamination from the anterior urethra, ≥105/ml of urine (8,9). 
 
Urinary tract infections can be anatomically distinguished into upper (kidney) and lower 
infection (bladder, prostate and urethra). This distinction can be useful as infections in the lower 
division of the tract commonly cause dysuria, frequency and urgency. While pyelonephritis 
(inflammation of the renal parenchyma) gives a clinical picture of chill and fever, flank pain 
and constituent symptoms due to bacterial invasion of the kidney. It is however important to 
remember that localizing the site of infection based on symptoms and signs can be inaccurate. 
With the help of urethral catheterization it has been detected that approximately 50% of women 
with asymptomatic bacteriuria had infection in their upper tracts, which confirms the inaccuracy 
of using symptoms for localization of infection (8,9). 
 
Another distinction that is important and generally used for the best management of 
patients with urinary tract infections, is the one between uncomplicated infections and 
complicated. Uncomplicated urinary tract infections refer to episodes of cysto-urethritis, 
following bacterial colonization of the ureteral and bladder mucosae to infection, in a 
structurally and neurologically normal urinary tract. In general, the following definitions are 
used: an uncomplicated UTI is an episode of cystitis in a woman who is not pregnant, is not 
immunocompromised, has no anatomical and functional abnormalities of the urogenital tract, 
and does not exhibit signs of tissue invasion and systemic infection. Those infections that are 
accounted for as complicated are defined as ones that have an increased risk for complications. 
These include those involving the parenchyma (pyelonephritis or prostatitis) and frequently 
evolve in the setting of obstructive uropathy or after catheterization. The presence of 
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obstruction, stones or high-pressure vesico-ureteric reflux, perinephric abscess, life-threatening 
septicemia or a combination of these predispose to kidney damage. Infective episodes may also 
be refractory to therapy. Refractions often result in relapses and occasionally leads to significant 
complications such as sepsis, metastatic abscess and rarely acute renal failure (8,9) (Figure 4).  
 
 
Figure 4. Classification of complicated and uncomplicated urinary tract infection 
Source from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875701/#CIT6 
1.3 Pathophysiology of urinary tract infections 
Bacteria are the most common cause of urinary tract infections. As previously 
mentioned, there are three possible routes whereby bacteria can invade and spread within the 
urinary tract, the ascending, hematogenous, and lymphatic pathways In healthy patients the 
route of infection is most often caused by uropathogens originating from rectal flora that are 
entering the urinary tract via the urethra into the bladder. This route is called ascending and 
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uropathogens attach to and colonize urothelium of the distal urethra. This particular route is at 
additional risk in patients with soiling around the perineum, in patients with urinary catheters 
and in females that use spermicidal agents. The fact that urinary tract infections are much more 
common in sexually active women than in men gives support to the importance of the ascending 
route of infection. The female urethra is short and is in proximity to the vulvar and perianal 
areas making contamination likely. It has been shown that the organisms that cause UTI in 
women colonize the vaginal introitus and the periurethral area before urinary infection occurs. 
Once within the bladder, bacteria may multiply and then pass up the ureters, especially if 
vesicoureteral reflux is present, to the renal pelvis and parenchyma (8–10).  
 
Other differences in UTI prevalence between men and women result from a set of other 
factors, including the larger distance between the anus (the usual source of uropathogens) and 
the urethra in men, the dry environment around the male urethra and the antibacterial activity 
of prostatic ﬂuid. Risk factors associated with UTI in healthy men include intercourse with an 
infected female partner, homosexuality and lack of circumcision but very often none of these 
factors is present in men with UTI (9,11). 
 
 In individuals with an intact health an infection of the kidney through the 
haematogenous route is uncommon. It does occasionally happen that the renal parenchyma may 
be breeched in patients with Staphylococcus aureus bacteremia or Candida fungemia that 
originate from oral sources in immunosuppressed patients. On other rare occasions bacteria 
from nearby organs may penetrate the urinary tract via the lymphatics. Conditions that spread 
via the lymphatic route are retroperitoneal abscesses and severe bowel infections (8,9). 
  
1.4 epidemiology and etiology 
Urinary tract infections (UTIs) are among the most commonly experienced infections 
by humans after respiratory and gastro-intestinal infections. In actuality, bacterial infections of 
the urinary tract are the most common cause of both community acquired and nosocomial 
infections for patients admitted to hospitals. It is a distressing infection and can at rare occasions 
even be life threatening (5).  
 
The microbial etiology of urinary tract infections has for several decades been regarded 
as reasonably consistent. The predominant uropathogen that continues to be isolated in patients 
with acute uncomplicated cystitis and acute uncomplicated pyelonephritis is E.coli (10). 
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Although there is a great difference between the bacterial flora of the urine in patients with an 
initial episode of UTI compared with the flora from frequent recurrences of infection, E.coli is 
the most frequent pathogen in acute infection. In recurrent UTIs, especially in the presence of 
structural abnormalities in the urinary tract (e.g., obstructive uropathy, congenital anomalies, 
neurogenic bladder, and fistulous communication involving the urinary tract) the relative 
frequency of infection caused by Proteus, Pseudomonas, Klebsiella, Enterobacter spp. and by 
enterococci and staphylococci increases greatly. In the presence of structural abnormalities, it 
is also relatively common to isolate not only one but multiple organisms from the urine (6,10). 
 
The environment in hospitals and long-term care facilities is an important determinant 
of the nature of the bacterial flora in urinary tract infection. Proteus, Klebsiella, Enterobacter, 
and Pseudomonas and staphylococci and enterococci are more often isolated from inpatients, 
compared with a greater occurrence of E.coli in an outpatient population (6,10). Anaerobic 
organisms are rare pathogens in urinary tract infections. Other various bacteria may on the other 
hand be found the urine in specific clinical settings. Fungi (particularly Candida spp.) occur in 
patients with indwelling catheter that are receiving antimicrobial therapy. Coagulase- negative 
staphylococci are a common cause of urinary tract infection in some cases. Staphylococcus 
saprophyticus, which is coagulase negative, tends to cause infection in young females who are 
sexually active. Coagulase-positive staphylococci most often reach the kidney from the 
hematogenous route, resulting in intrarenal or perinephric abscesses (6,12) (Figure 5).  
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Figure 5. Common causes of UTIs in community and hospital setting 
Source from http://schoolbag.info/biology/microbiology/21.html 
 
1.5 Risk Factors 
There are several predisposing factors that increase the risk of urinary tract infections 
including age, diabetes, benign prostatic hypertrophy, spinal cord injury, or catheterization, 
chronic diseases such as dementia and Alzheimer, all of these have a great impact on the 
etiology of UTIs. Less virulent organisms that rarely cause disease in a normal urinary tract can 
cause significant illness and invasive disease in an abnormal host with anatomic, metabolic or 
immunologic underlying disease. This results in the fact that complicated UTIs have a more 
diverse etiology than uncomplicated UTIs (10,11). 
  
The etiology of UTIs in older patients depends on their general health status and whether 
they reside independently in the community or need long-term care. The majority of 
community-acquired symptomatic uncomplicated infections in elderly women are caused by E. 
coli. S. saprophyticus is a rare pathogen in this subpopulation if compared to younger sexually 
active women. Gram-positive organisms on the other hand are common and account for 10% 
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to 20% of UTIs in the older population. Polymicrobial infections are also more common in this 
population accounting for up to 1 in 3 patients. Another important note is that the high rate of 
urinary catheterization among the elderly in long-term care facilities in combination with the 
frequent use of systemic antibiotics, increases the risk of UTIs caused by resistant gram-
negative bacteria such as Pseudomonas aeruginosa (10).  
 
UTIs are considered to be one of the top concurrent illnesses with diabetes. The 
epidemiology between men and women with diabetes and without is quite similar. Women are 
at a greater risk of getting the infection in general however sexual activity and its frequency is 
also a factor that must be taken into account. The bacteriology and antibiotic susceptibility 
patterns in the general sense also do not differ from those without diabetes. On the other hand 
diabetic patients are more likely to have asymptomatic bacteriuria wich does not mean that 
there is an increased risk of symptomatic infection itself. Diabetes does however double the 
risk of UTI but the reason for this increase is not well understood, although bladder dysfunction, 
which increases with duration of diabetes and glycosuria are thought to be hypothetic 
mechanism (10,13).  
 
Catheter-associated urinary tract infections remain the most common type of 
nosocomial infection and are a major health concern in hospitals and long term facilities. 
Indwelling urinary catheters are standard medical devices used to relieve urinary retention and 
urinary incontinence. Due to the frequent and sometimes unnecessary use of indwelling 
catheters during hospitalization, the risk of UTI increases by 5–8% a day of catheterization and 
is inevitable in long-term catheterized patients (14,15). Patients that require an indwelling 
catheter are as mentioned predisposed to the development of catheter-associated urinary tract 
infections but they are also at an increased risk for potentially pathogenic multidrug-resistant 
organisms. Despite the constant threat of infection from opportunistic nosocomial 
multiresistant strains, most cases of catheter-associated bacteriuria or the presence of bacteria 
in the urine are asymptomatic. The microorganisms that are often encountered in this sort of 
UTIs are exogenous microorganisms, such as P.aeruginosa or endogenous ones such as E.coli, 
S.epidermidis, S. saprophyticus, Proteus spp. and Klebsiella spp (16). 
 
Neurogenic bladder is another risk factor that can be caused by traumatic spinal cord 
and brain injuries, strokes, cauda equina lesions and other diseases such as multiple sclerosis. 
The severity and location of the injury determine the degree and duration of the dysfunction of 
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the bladder. Nearly all of these patients will experience bladder dysfunction with its resulting 
increased risk of UTIs. The general prevalence in Europe has been stated as 15.6% of men and 
17.4% of women. The microbes involved in an UTI affecting a patient with a neurogenic 
bladder are the same as any other patient, the specific incidence varies. The rates are: E.coli 
60% to 65%, P. mirabilis 14%, K.pneumoniae 10%, Staphylococcus species 4%, and then other 
enterobacteria. There are some variations between men and women that have been reported 
with the predominant organism being E.coli in women and in men Gram-positive cocci. An 
important note is that, it has been identified that E.coli colonization does not increase the risk 
of symptomatic disease or deterioration of the upper urinary tract (11).  
  
1.6 Clinical picture and complications 
Accounted for in uncomplicated urinary tract infection is cystitis (infection of the 
bladder or lower UTI) and has the following symptoms: dysuria with or without frequency, 
urgency, suprapubic pain, or hematuria. Urinary frequency is the most common presenting 
symptom. Dysuria is also quite common with urethritis or vaginitis, but cystitis is more likely 
when symptoms include frequency, urgency, or hematuria and when the onset of symptoms is 
sudden or severe, without the presence of vaginal irritation and discharge. Those patients that 
are not given antibiotics, and those with antibiotic resistant organisms, complain of at least one 
symptom that is moderately severe or worsening and lasting for five days. Cystitis being the 
probable cause is greater than 50% in women with any symptoms of UTI and greater than 90% 
in women who have dysuria and frequency without vaginal discharge or irritation. That is the 
reason why additional urine analysis is not always needed in this patient group. Acute 
uncomplicated cystitis rarely progresses to severe disease, even if untreated (17,18). 
 
Complicated infections are UTIs in a host, which has an increased risk to develop 
complications (complicated host). A complicated host is defined as one that has an increased 
risk for complications of the UTI, such as the following men, pregnant women, 
immunocompromised patients, or those who have an anatomical or functional abnormality of 
the urogenital tract (e.g., renal stones, urinary catheter, neurogenic bladder, diabetes, dementia  
spinal cord injury, renal transplant and so on).  Systemic symptoms can be noticed by signs of 
tissue invasion, like fever, flank pain, and delirium. These UTIs can be called febrile UTI and 
include urosepsis, pyelonephritis, and prostatitis (17,18). 
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In acute pyelonephritis the typical clinical manifestations suggestive of the infection are 
fever (temperature >38°C) and chills, mental confusion as a sign of delirium, flank pain, 
costovertebral-angle tenderness, and nausea or vomiting. Symptoms may vary profusely and 
flank tenderness may be more intense when an obstructive disease is present. Normal kidney 
function can be present, but progressive destruction of the kidney may give rise to clinical 
manifestations of renal insufficiency (17,19). 
 
Prostatitis is an infection that has quite a variable range of clinical signs, from a 
straightforward clinical entity in its acute form to a complex, debilitating condition when 
chronic. Patients with acute prostatitis complain of symptoms associated with lower UTI, such 
as frequency and dysuria. They may as well experience lower urinary-tract obstruction due to 
prostatic edema. On physical examination, patients may show signs of a high temperature and 
lower abdominal or suprapubic discomfort due to bladder infection. The rectal examination 
shows a tender prostate on palpation but the diagnosis can not be excluded due to a normal 
rectal examination (17,20). UTIs in a men are generally considered to be complicated UTIs 
because the prostate is often involved. However, men with a bacterial UTI can be separated 
into three groups. Young men with a UTI without systemic symptoms where there is no 
suggestive a causative factor. The UTIs in this group are considered to be uncomplicated UTIs, 
but are uncommon. The second group are men with a UTI and systemic symptoms or with a 
causative factor in their medical history or physical examination. These UTIs are considered as 
complicated UTIs. The systemic symptoms indicate invasion of the tissue in the prostate (acute 
bacterial prostatitis) or the kidney (pyelonephritis). The third group consists of men with 
chronic bacterial prostatitis. In these cases, it is advised to wait for the results of the culture 
(21,22).  
 
The term urosepsis is commonly used to describe the sepsis syndrome caused by urinary 
tract infection and is considered to be a complication. The severity of sepsis mainly depends on 
the response of the host. The underlying UTI is almost exclusively a complicated one with 
involvement of parenchymatous urogenital organs (e.g., kidneys, prostate). The leading cause 
for developing an uroseptic shock in urological patients is urinary obstruction. It is reported 
that 17% of patients develop urosepsis after urological interventions. Urosepsis relates to 
clinical evidence of urinary tract infection plus two or more of the following: temperature, 
>38,0 C or <36,0 C,  heart rate > 90 beats/min,  respiratory rate > 20/min or PaCO <32 mm Hg, 
white blood count, >12,000/mm3,< 4,000/mm3 or >10% band forms (6,17). 
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Recurrent UTIs are a common health care problem and are defined as three episodes of 
UTI in the last 12 months or two episodes in the last 6 months. About 20 to 30% of women 
who have a UTI will have a recurrent UTI, which is a relapse. Relapse is a return of infection 
due to the same micro-organism which is often drug resistant. It is defined as the recurrence of 
bacteriuria with the same organism within three weeks of receiving treatment, which during 
treatment resulted in sterile urine. Relapse implies that there has been a failure to eradicate the 
infection. This most often occurs in association with renal scars, stones, cystic disease or 
prostatitis and in patients with chronic interstitial disease or in those who are immune 
compromised. Reinfection on the other hand is a recurring infection due to a different 
microorganism that is usually drug susceptible. Most recurring episodes of cysto-uretheritis are 
due to reinfections that are much more common than relapses and accounts for about 80% of 
recurrent infections. Unlike relapse, reinfection does not mean failure to eradicate infection 
from urinary tract but is due to recolonization of the system (8,23). 
 
1.7 Diagnosis 
The initial step in the diagnosis of UTIs is to obtain a thorough medical history and conduct 
a thorough physical examination in order to distinguish those patients with infection and to 
identify predisposing risk factors defining a complicated UTI. 
 
The diagnosis of acute uncomplicated cystitis can be made with high probability based on 
a focused history of lower urinary tract symptoms (dysuria, frequency and urgency) in a patient 
who has no risk factors for complicated UTI. Urine dipstick analysis, as opposed to urinary 
microscopy, is a reasonable alternative to urine culture to diagnose acute uncomplicated 
cystitis. Urine cultures are recommended for patients with risk factors for complicated UTIs.
  
In a microscopic examination of urine, in a centrifuged sediment, patients with significant 
bacteriuria almost always show bacilli in the urine, whereas only a small amount of patients 
with less than 105 colony forming units per ml show bacteria. In significant bacteriuria about 
60-85% of patients have 10 or more white blood cells per high power field in mid-stream urine.  
When it comes to pyuria 95 % of patients have some form of genitourinary tract infection; 
although, pyuria cannot distinguish between a bacterial UTI and an acute urethral syndrome. 
Simple gram-stained smears can be helpful in specifying the morphology and stain 
characteristics which can aid in identifying the likely pathogen and in targeting empiric therapy. 
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Urine culture is the only certain way to establish diagnosis of UTI from simple cystitis to 
complicated pyelonephritis with sepsis.  
 
Imaging should be considered if urinary tract infection is slow to resolve, if there is 
relapse or if there are risk factors for papillary necrosis. It should be done 3-6 weeks after cure 
of acute infection to identify abnormalities predisposing to infection or renal damage or which 
may affect management. It is rarely carried out in the acute phase, particularly where there is 
severe loin pain. It is important to recognize that abnormalities will be found in less than 5 % 
of unselected cases. Patients who have severe loin pain or whose infection does not settle on 
treatment should have US and plain X-ray to exclude pyelonephrosis, intrarenal or perinephric 
sepsis or calculi. CT may be undertaken if no abnormality is seen on US in such patients. There 
is no indication for imaging, in women, following a single or infrequent infection. Recurrent 
attacks more often than 2 per 6 months should be investigated by ultrasound and plain xray, 
since this is the imaging of choice in these cases. In men, UTI is much less common than in 
women, and imaging is indicated after the first documented bacteriuria to exclude predisposing 
factors especially impaired bladder emptying. USG and plain film are the best first choice 
(5,24,25). 
 
1.8. Treatment 
 The choice of treatment for UTIs depends on whether it is uncomplicated or 
complicated. The antimicrobial agents most commonly used to treat uncomplicated urinary 
tract infections include the combination drug trimethoprim and sulfamethoxazole, 
trimethoprim, β-lactams, fluoroquinolones, nitrofurantoin, and fosfomycin tromethamine. 
These agents are used primarily because of their tolerability, spectrum of activity against 
suspected uropathogens, and favorable concentration of the antimicrobial agent in the urine 
rather than serum levels. All the antimicrobial agents approved for the treatment of urinary tract 
infections achieve inhibitory urinary concentrations that significantly exceed serum levels. 
Also, agents such as trimethoprim-sulfamethoxazole or the fluoroquinolones that eradicate 
aerobic gram-negative flora but have little effect on the vaginal and fecal anaerobic flora seem 
to provide the best long-term cures for uncomplicated urinary tract infections (26,27). Due to 
the fact that most uncomplicated urinary tract infections are treated empirically, it is important 
for clinicians to be aware of the resistance patterns of uropathogens in their own community to 
ensure that the most appropriate antimicrobial agent is used. The emergence of resistant 
uropathogens has had a tremendous effect on empiric therapy in the last years. The most 
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dramatic increase in resistance in the past few years has been to trimethoprim-
sulfamethoxazole. Another increase in resistance has been of E.coli to β-lactams such as 
ampicillin and first-generation cephalosporins which was 34% and 28%, respectively (27,28). 
Trimethoprim-sulfamethoxazole should be used as first-line therapy because of its low cost and 
efficacy for uncomplicated urinary tract infections in women unless the prevalence of resistance 
to these agents among uropathogens in the community is greater than 10% to 20%. The 
fluoroquinolones are more expensive, broader in spectrum, and therefore, should be reserved 
for communities with rates of resistance to trimethoprim of greater than 10% to 20% or in 
patients who either cannot tolerate trimethoprim-sulfamethoxazole or have recurrent urinary 
tract infections. Other options include a 7-day course of nitrofurantoin or a single dose of 
fosfomycin. The use of first-generation cephalosporins or aminopenicillins is generally not 
recommended because of high levels of resistance and recurrence. Although resistance to the 
third-generation cephalosporins is lower than to the first generation, these agents are considered 
third-line agents because of their cost and efficacy (29,30). 
 
 The main goal of managing complicated UTIs is optimal administration of appropriate 
antimicrobial agent and correction of any underlying genitourinary abnormalities. Optimal 
administration includes a treatment given on time, appropriate selection and dosing of 
antimicrobial agents to which the potential pathogen is susceptible to. In order to select an 
appropriate empiric therapy, clinicians must be well aware of the institution-specific resistance 
patterns. Once culture and sensitivity reports are available, therapy should be adapted 
accordingly. In addition, therapy selection is influenced by host-specific factors such as, 
previous anti-infective exposure, severity of signs and symptoms, allergy history, and organ 
dysfunction (31,32). 
 
 Antimicrobial resistance is commonly encountered in complicated UTIs for many 
reasons. These patients have recurrent infections frequently and receive repeated courses of 
antimicrobial therapy. In addition, patients may acquire infection nosocomially through 
instrumentation (catheters) and organisms acquired this way are more likely to be resistant than 
those acquired in the community (33,34). Antimicrobial resistance is a concern for gram-
negative organisms since these represent the dominant etiology of complicated UTIs. There is 
a global indication of increased rates of resistance in uropathogens in general. Although the 
specific concerns relate to multi-drug resistance, as there is an increased incidence of AmpC β-
lactamases and extended-spectrum β-lactamase (ESBL)–producing organisms (35). 
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 E.coli is becoming increasingly resistant to first-line antimicrobial therapy. Resistance 
of E.coli to trimethoprim-sulfamethoxazole (TMP-SMX) and fluoroquinolones is 21% to 28% 
and 7% to 40%, respectively(36,37). The greatest risk factors for the increased resistance of 
TMP-SMX and fluoroquinolone in E.coli are high levels of TMP-SMX and fluoroquinolone 
being prescribed in the health care setting and residency in long-term care facilities (38,39) On 
the other hand, the resistance rates of E.coli to carbapenems, cephalosporins, and 
piperacillin/tazobactam remained low and stable (28). Carbapenems are considered the drugs 
of choice for the treatment of severe infections due to ESBL-producing Enterobacteriaceae. 
Other agents that could be useful in the treatments of of ESBL-associated UTIs include 
fosfomycin, nitrofurantoin, tigecycline, polymyxins, and aminoglycosides depending on 
susceptibility. Fosfomycin and nitrofurantoin should only be used for the treatment of lower 
UTIs and are contraindicated in patients with pyelonephritis (40). Aminoglycosides can be used 
to manage UTIs caused by ESBL-producing bacteria despite the associated toxicity but there 
has been a recent increase with the worldwide emergence of resistant E.coli in the community 
setting (28,41). AmpC β-lactamases are clinically important cephalosporinases encoded on the 
chromosome of many Enterobacteriaceae and a few other organisms where they mediate 
resistance to cefazolin, cefotaxime, ceftazidime, and ceftriaxone, most penicillins, and β-
lactamase inhibitor/β-lactam combinations. They can appear in E.coli, K.pneumoniae, and P. 
mirabilis. AmpC β-lactamase–producing E.coli is an emerging community pathogen that 
commonly causes UTIs in older women. Carbapenems are the drug of choice for serious 
infections caused by these organisms, but if the isolate is susceptible, fluoroquinolones are 
considered to be a fitting option for the treatment of non–life-threatening UTIs caused by AmpC 
β-lactamase–producing organisms (42).  
 
 Carbapenems are considered optimal choices for mixed infections as they exhibit a 
broad spectrum of activity versus Gram-negative and Gram-positive organisms, including 
ESBL- and AmpC-producing organism (43).  
 
High-dose fluoroquinolones such as levofloxacin might be successful in treatment of 
mild UTI with fluoroquinolone-resistant, Gram-negative uropathogen. Although it should be 
taken into consideration that fluoroquinolones should not be used as empiric treatment of 
complicated UTIs, in patients with recent use of fluoroquinolones, recurrent UTIs, and recent 
hospitalization due to the emergence of fluoroquinolone resistant uropathogens (28,44). 
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Traditionally, an aminoglycoside alone or in combination with a β-lactam has been considered 
a first-line option for the management of complicated UTIs and they are frequently 
recommended as a therapeutic option. The downside of these antibiotics is that they continue 
to be associated with an increased risk of nephrotoxicity and ototoxicity. Therefore they should 
be reserved for the treatment of complicated UTIs where other safe and effective antimicrobial 
agents are not appropriate (28,45). 
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2. OBJECTIVES 
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The aims of the study were 
1. To analyze the predisposing factors in a patient with an infection in the urinary tract system 
2. To analyze the most common causative pathogens of urinary tract infections. 
3. To analyze the antibiotic sensitivity of the most common causative pathogens of urinary tract 
infections, and to this way conclude the proper choice of initial empirical antibiotic therapy for 
all our patients.    
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3. MATERIALS AND METHODS 
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3.1 Study population 
 In this study 175 patients were included with the diagnosis cystitis, pyelonephritis and 
prostatitis, with no proven bacteremia, which were treated at the Clinic of Infectology at the 
University Hospital of Split, in the period of years 2016-2017. All patients were diagnosed on 
the basis of clinical evaluation and laboratory diagnostics.   
3.2. Study Design 
This study was conducted as an observational retrospective study. 
3.3. Method of collecting and analyzing data 
 Medical data of eligible patients was retrieved from a written protocol at the Clinic of 
Infectology at the University Hospital of Split and collected by reviewing the history of medical 
files from the archive. The collected data was then inserted in Microsoft Office packages in 
Microsoft Excel program.  
3.4 Research Method 
By using the medical history and discharge papers of our patients, the occurrence of 
urinary tract infections in certain age groups, in both genders were analyzed. On the basis of 
the collected data about comorbidities possible risk factors were analyzed together with the 
amount of patients with the possibility of more than one comorbidity. With the use of 
microbiological test results in urine cultures the etiology of urinary tract infections and their 
sensitivity to the main groups of antibiotics were analyzed.   
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4. RESULTS 
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In Table 1. the distribution of patients by age and gender is shown. The mean age of the 
patients was 60.6 years. The mean age for females was 57.7 years. The mean age for males was 
65.5 years. The largest number of patients (27.4%) were in the age group from 80 years and on. 
Most of the patients were women (61.1%). 
 
Table 1. Distribution of patients with urinary tract infection (UTI) according to age and sex 
Age (years) Female 
Number (%) 
 
Male  
Number (%)  
Total  
Number (%) 
19 3 (1.7) 2 (1.1) 5 (2.9)                     
20-39 33 (18.9) 3 (1.7) 36 (20.7) 
40-59 17 (9.7) 17 (9.7) 34 (19.4) 
60-69 12 (6.9) 12 (6.9) 24 (13.7) 
70-79 18 (10.3) 10 (5.7) 28 (16.0) 
≥80 24 (13.7) 24 (13.7) 48 (27.4) 
Total   107 (61.1) 68 (38.9) 175(100.0)  
 
Table 2. shows the distribution of clinical diagnosis among the patients. The largest 
number of patients, 85.1% had pyelonephritis and only 2.3% had cystitis as a clinical diagnosis. 
 
 
Table 3. presents the distribution of patients with the number of predisposing conditions. 
Most patients had no known predisposing condition, 38.3% had 2 or less than 2 predisposing 
conditions. Only 10.9% had 3 or more predisposing conditions. All together there were 86 
patients (67+19) with some kind of know predisposing factor.  
 
Table 2. Clinical diagnosis of patients with UTI 
Diagnosis   Number (%) 
Pyelonephritis  149 (85.1) 
Cystitis  4 (2.3) 
Prostatitis/prostatocystitis 22 (12.6) 
Total 175 (100.0) 
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Table 3. Distribution of patients with UTIs according to the number of predisposing 
conditions 
Number of predispositions      Number of patients (%) 
No   89 (50.9) 
 2  67 (38.3) 
≥ 3  19 (10.9) 
Total 175 (100.0) 
 
Table 4. gives a representation of  the predisposing factors related to urinary tract 
infections. Some patients had more then one predisposing condition which is seen in Table 3. 
The most common predisposing factor is diabetes mellitus with 14.9%, followed by 
neurological urine incontinence/retention with 13.7%. Abdominal malignancies affecting the 
urinary tract and obstructive uropathies were the predisposing conditions with the lowest 
number of patients, 2.3%.  
 
 
Table 5. shows the etiology of urinary tract infections acquired from urine culture. The 
most common isolate by far was E.coli with 62.8%, followed by P.aureginosa with 10.2%. At 
third place was P.mirabilis with 8.2%.  
 
Table 4. Predisposing conditions in patients with UTIs 
Condition  Number of patients (%)  
Urinary catheter 13 (7.4) 
Neurological urine incontinence/ retention 24 (13.7)  
Urinary tract stones 8 (4.6)  
Benign prostatic hypertrophy 8 (4.6)  
Urinary tract malignancy 9 (5.1)  
Other abdominal malignancies affecting 
urinary tract 
4 (2.3)  
Other obstructive uropathies (hydronephrosis) 4 (2.3)  
Diabetes mellitus 26 (14.9)  
Other chronic diseases 9 (5.1)  
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Table 5. Etiology of UTI  
Agent Urine culture 
[number (%)] 
    
E. coli  
Klebsiella  
P. mirabilis 
P.aureginosa 
M.morgagnii 
Citrobacter 
E.faecalis 
E.faecium 
S.saprophyticus 
S.aureus 
S.aerogenes 
A.baumanii 
E.cloacae 
123 (62.8) 
11 (5.6) 
16 (8.2) 
20 (10.2) 
6 (3.1)  
4 (2.0) 
7 (3.6) 
1 (0.5) 
1 (0.5) 
1 (0.5) 
1 (0.5) 
4 (2) 
1 (0.5) 
  
Total 196(100.0)   
 
Table 6. shows the sensitivity and resistance of E.coli to different antibiotics. The 
resistance was highest towards ampicillin 48.0%. Trimetroprim-sulfamethoxazole was the 
second antibiotic in exhibiting resistance in E.coli with 29.3%, followed by fluoroquinolones. 
Amoxicillin-clavulanic acid showed low resistance, 7.0% and high sensitivity, 93.5%. No 
isolates of E.coli were found to be resistant to Carbapenems. 
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Table 7. shows the distribution of different pathogens and their resistance to antibiotics. 
Only 3 A.baumanii, 1 P.mirabilis and 1 P.aureginosa isolates were found to be resistant against 
Carbepenem. The most occurring resistance was in E.coli where 35 isolates were Trimetoprim-
sulphametoxazole resistant. The second most occurring resistance was also found in E.coli 
where 26 isolates were resistant to quionolones. Klebsiella species showed resistance to several 
antibiotics in the 11 isolates, where 5 isolates were ESBL+ and 5 were quinolone resistant. 
 
. Table 7. Distribution of causative organisms of UTI according to their antibiotic resistance 
 
 
Organism  
 
No of 
isolates  
Antibiotic resistant isolates [number (%)] 
Amox-clav R* ESBL+** CR$  Quionolone R TMP/SMX#  R 
E. coli 124 7 (5,6) 20 (16,1) 0 26 (21,0) 35 (28,2) 
Klebsiella 11 3 (27,3) 5 (45,5) 0 5 (45,5) 4 (36,4) 
P.mirabilis 16 0 0 1 (6,3) 7 (43,8) 3 (18,8) 
P.aureginosa 20 na+ 3++ (15) 1(5) 5 (25) na 
M.morgagnii 6 5 (83,3) 0  0 0 4 (66,7) 
Citrobacter 4 2 (50) 0 0 0 0 
Enterococcus 7 1 (14,3) na Na 3 0 
A.baumanii 4 0 0 3 (75) 2 0 
Legend  
*Amox-clav R: amoxicillin-clavulanate  resistant; **ESBL+: extended β-lactamase positive; $CR- carbapenem resistant; 
#TMP/SMX R:Trimetoprim-sulphametoxazole resistant; +na: not available;  3++: 3 P.aeruginosa isolates were resistant to 
cefatizidim and piperacillin-tazobactam  
Table 6. Antibiotic sensitivity of Esherichia coli in patients with UTI 
Antibiotic  Sensitive  
(Number (%)) 
Resistant 
(Number (%))  
Total 
Number 
Ampicillin  64 (52.0) 59 (48.0) 123 
Amoxicillin-clavulanic acid 115 (93.5) 8 (7.0) 123 
Carbepenem 123 (100.0) 0 123 
Cephalosporins 1 and 2nd generation 102 (83.0) 21 (17.1) 123 
Cephalosporin 3  105 (85.4) 18 (14.6) 123 
Trimetroprim-sulfamethoxazole 87 (70.7) 36 (29.3) 123 
Fluoroquinolones 95 (77.2) 28 (22.8) 123 
Aminoglycosides 111 (90.2) 12 (10.1) 123 
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5. DISCUSSION 
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Urinary tract infections are among the most commonly experienced infections by 
humans after respiratory and gastro-intestinal infections that can occur at any age (5). However 
there is a difference in the prevalence between men and women. In our patients there was a 
significantly greater number of women (61.1%) then men (38.9%) and this difference is most 
prominent up until the age of 39. The greatest difference between the two genders was in the 
age group 20-39 where 33 women and 3 men had the infection. This great difference between 
sexually active women and men is related to a set of other factors, including the larger distance 
between the anus (the usual source of uropathogens) and the urethra, the dry environment 
around the male urethra and the antibacterial activity of prostatic ﬂuid. The female urethra is 
also shorter than the male one and is in proximity to the vulvar and perianal areas making 
contamination likely (8–10). 
As the age increases the incidence of urinary tract infection in men also increases. In 
our patients the incidence is especially high in men affected by the infection from 80 years and 
onward, more then 1/3 of the total amount of male patients reside in this age group. This 
increase in infection rate as men age is due to acquired structural and functional abnormalities 
of the urinary tract that impair normal voiding; the most common being, benign prostatic 
hyperplasia, which can cause urinary tract infection owing to obstruction and turbulent urine 
flow (46-48). When it comes to the fact, that the number of men and women in the higher age 
groups is equal in number, this is not supported by scientific literature. It still states that women 
are the most commonly affected gender even in the older age groups. Although a greater 
number of patients, in the higher age groups, would have been needed in our study to conclude 
anything. However literature also states that accurately measuring the incidence of urinary tract 
infections in the elderly is difficult since criteria used for diagnosis are not consistent across 
epidemiologic studies. In our study the highest number of patients were in the age group from 
80 years and on, which correlates with the general fact that incidence of infection increases 
with age (46). 
In our research patients without positive hemoculture were documented. Amongst those 
patients 85.1% had pyelonephritis as a diagnosis, 12.6% patients had prostatitis/prostatocystitis 
and the lowest number of patients had cystitis 2.3%. This sort of division of clinical symptoms 
was to be expected as pyelonephritis is clinically more severe and easier to detect than acute 
prostatitis. While patients with cystitis are rarely hospitalized and if so it occurs in situations 
where parenteral antibiotic treatment is the only choice of treatment (17,20).   
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There are several predisposing factors that increase the risk of urinary tract infections 
including age, diabetes, benign prostatic hypertrophy, spinal cord injury, catheterization, 
chronic diseases and all of these have a great impact on the etiology of urinary tract infections 
(10,11). In our patients 50.9 % had predispositions known to us, 38.3 % had 2 or less 
predispositions and 10.9 % had 3 or more predispositions. All together 89 patients had no 
predispositions while 86 patients had some kind of known predispositions. This does not 
exclude the fact that there is an increased risk of disease with these factors. Articles do state 
that with age patients have more of the above mentioned risk factors such as catheter, diabetes, 
urinary disturbances and so on (11,46). What would have been interesting to add in our study, 
which is also a limitation is, the relation of age and predispositions. To see how many patients 
in the different age groups, between the two genders, had predispositions that increase the risk 
of urinary tract infections. 
As expected and in accordance to literature different kinds of disruption of the normal 
urinary flow, when combined, are the most common predisposing factors of urinary tract 
infections. Our study had 24 patients with neurologic factors, 13 with urinary catheters, 8 with 
urinary tract stones, 8 with benign prostatic hypertrophy and 4 with obstructive uropathies, this 
results in a combination of 57 patients with disrupted urinary flow. Among our patients, 
neurologic factors (immobility, Alzheimer’s, dementia, multiple sclerosis with resulting urinary 
incontinence/retention) were the second most common predisposition for infection (10,11). The 
most common predisposing factor in our study was diabetes mellitus with 26 patients in total. 
There is a known increased risk of developing urinary tract infections with diabetes mellitus. It 
is actually considered to be one of top ten risk factors for urinary tract infections and has quite 
an increase in incidence with age (10,13). The rest of the predisposing factors in our study cause 
anatomic, metabolic or immunologic disease which all give an increased risk (10,11). All of 
these patients with predisposing conditions are considered to have complicated urinary tract 
infections (17,18). The predisposing factors mentioned increase with age and less virulent 
organisms, that rarely cause disease in a normal urinary tract, can cause significant illness and 
invasive disease with one of the mentioned predisposing factors (46). This results in the fact 
that complicated UTIs have a more severe disease outcome than uncomplicated UTIs (10,11). 
The limitation in our study in this section was the lack of the relation of age and predispositions, 
to see what specific predispositions occurred the most in what age groups, between the two 
genders, with a more extensive number of patients. 
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Amongst our patients E.coli (62.8%) was by far the most common cause of urinary tract 
infections, in second place was P.aureginosa (10.2%) followed by P.mirabilis (8.2%), 
Klebsiella (5.6%) and the remaining isolates were even fewer in number. What is of great 
importance to notice is that in our study we did not differentiate between community acquired 
and hospital acquired pathogens. In literature, in a community acquired setting, Escherichia 
coli accounts for 75% to 90% of cases, Klebsiella species and Proteus mirabilis, account for 
the remaining 5% to 10% (27).  When looking at literature for hospital acquired infections the 
most commonly isolated pathogens are E. coli (35.3%), Enterococcus sp. (15.2%), Klebsiella 
sp. (9.8%) and Pseudomonas aeruginosa (5.4%) (49-51). E.coli is more prevalent in a 
community acquired setting while other pathogens, such as P.aureginosa, P.mirabilis and 
Klebsiella species are more prevalent in a hospital acquired setting. When comparing our study 
to the percentages of community acquired isolates, we have a lower number of E.coli isolates. 
Which could be explained by the fact that we had some hospital acquired or recurrent infections 
and a higher number of bacteria (P.aureginosa, P.mirabilis, Klebsiella species) that are more 
prevalent in hospital infections.  
  There has been a great increase in resistance among Enterobacteriacae around the world. 
These bacteria, including E.coli, have acquired a high prevalence of resistance against 
penicillins such as ampicillin even when community acquired infections are considered. The 
resistance of E. coli to b-lactams, such as ampicillin, and the first-generation cephalosporins 
has continued to increase in the past decade and now approaches 40% in most studies (28,27). 
In an extensive susceptibility study in Croatia, the resistance of E.coli to ampicillin is even 
higher accounting for 50% in 2016 (49). This correlates with our study, where 48.0% of the 
E.coli isolates where resistant to ampicillin. Logically this excludes ampicillin from any kind 
of first choice for empirical treatment of urinary tract infections. The percentage of resistance 
might have been somewhat lower in exclusively community acquired isolates, which was not 
studied in our patients. This would have still not rendered ampicillin for empirical use. The 
resistance of E.coli isolates against amoxicillin-clavulanic acid was only 7.3%, which closely 
correlates with the resistance in Croatia (49). Therefore amoxicillin-clavulanic acid is an 
appropriate first choice of empirical treatment for community acquired urinary tract infections. 
If it would be equally appropriate for hospital acquired infections was not studied in our 
patients. Another antibiotic to which E.coli has a great increase in resistance is trimethoprim-
sulphametoxazole, especially in hospital settings. In literature the resistance of E.coli to 
trimethoprim-sulfamethoxazole is 21% to 28% (36,37). In studies done in Croatia the resistance 
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against this antibiotic is at 27% (49). Our patients had a resistance of 29.3% which correlates 
well with the previous studies mentioned above. This however excludes trimethoprim-
sulfamethoxazole as a first choice antibiotic for empirical treatment and it is therefore only an 
option once susceptibility to it has been confirmed.   
What was unexpected was the number of resistant isolates against third-generation 
cephalsporines which was 14.6%.This makes third generation cephalsporins less reliable then 
amoxicillin-clavulanic acid as a treatment option. Although no conclusion can be made since 
there is a lack of differentiation between community and hospital acquired infection in our 
study.  According to a Croatian study, the resistance is 6-9% to these antibiotics (49). In general 
in the EU/EEA the mean percentage of resistance to third-generation cephalosporins increased 
significantly from 9.5% in 2010 to 12.6% in 2013 (50).  
A Croatian susceptibility study showed a resistance of 19% in E.coli to fluoroquinolones 
(49). The EU/EEA population-weighted mean percentage for fluoroquinolone resistance was 
22.4 % in 2014(51). In our study 22.8% of our isolates were resistant to this antibiotic which 
would mean that it would not be considered as a good first choice for treatment. Again it is 
important to note that this number could be lower in infections acquired in community. This 
antibiotic is considered to be a good first choice treatment in uncomplicated urinary tract 
infections, according to literature (26,27).   
When the overall distribution of the causative organisms of UTI and their antibiotic 
resistance in our study are evaluated, E.coli is the dominant isolate. Amoxicillin-clavulanic acid 
is a reliable first line choice of empirical antibiotic treatment. The same seems to be correct for 
the treatment of P.mirabilis and to some extent for K.pneumoniae. However the low number of 
these two isolates makes it impossible to conclude anything. To be able to do that for the isolates 
with a low number, a more extensive study would be needed with greater number of patients 
and a differentiation between community and hospital acquired infection. But as it seems 
amoxicillin-clavulanic acid would be a reliable choice anyway. When it comes to Carbepenems, 
except for the expected resistance found in A.baumanii, there is basically no resistance to this 
antibiotic. Even though our study was limited by the lack of data to distinguish between 
community and hospital acquired infection, it is still obvious that carbepenems are very reliable 
in the choice of empirical treatment for hospital acquired urinary tract infections. This 
observation is concluded by scientific literature (42,43). 
 
33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. CONCLUSION 
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1. Half of our patients did not have any predisposing conditions for UTIs. The most common 
predisposing factors in our patients were diabetes mellitus, variety of neurological conditions 
that are associated with urin incontinence or retention, and long term urinary catheters. High 
age, especially above 80 years, is connected with an increased incidence of UTIs.  
 
2. In our patients, with a number over 60% the most common pathogen was E.coli, far behind 
it in second place was P.aureginosa with only 10.2%, and the rest of the bacteria were in a 
margin from 0.5-8.2%. 
 
3. Over 90% of E.coli isolates were sensitive to amoxicillin-clavulanic acid which makes this 
antibiotic a reliable first choice as an empirical treatment for community acquired UTIs. 
Trimethoprim-sulfamethoxazole, fluoroquinolone and to a certain degree cephalosporins 
should not be used before the antibiotic susceptibility of the pathogen is known. Carbapenems 
are reliable first choice antibiotics, but they should be reserved for patients with recurrent or 
hospital acquired UTIs.  
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OBJECTIVES: confirm the predisposing conditions, the most common causative pathogen and 
their sensitivity to different antibiotics in patients with urinary tract infections (UTIs).  
 
MATERIAL AND METHODS: the study included 175 patients with the diagnosis cystitis, 
pyelonephritis and prostatitis, with no proven bacteremia, which were treated at the Clinic of 
Infectology at the University Hospital of Split, in the period of years 2016-2017. All patients 
were diagnosed on the basis of clinical evaluation and laboratory diagnostics. Study was 
conducted as an observational retrospective study. Medical data were collected by reviewing 
the history of medical files from the archive of at the Clinic of Infectology.  
 
RESULTS: the largest number of patients (27.4%) were in the age group from 80 years and on. 
Most of the patients in the study were women (61.1%). Almost half of the patients (48.9%) had 
one or more predisposing conditions for UTIs. The most frequent predispositions were diabetes 
mellitus (14.9%), variety of neurological conditions that are associated with urin incontinence 
or retention (13.7%), and long term urinary catheters (7.4%). E.coli (62.8%) was by far the 
most common cause of urinary tract infections, in second place was P.aureginosa (10.2%) 
followed by P.mirabilis (8.2%), Klebsiella (5.6%). Almost half (48.0%) of the E.coli isolates 
where resistant to ampicillin, and only 7.3% were resistant to amoxicillin-clavulanate, while 
resistence to trimetoprim-sulphametoxazole and fluroquinolones was 29.3% and 22.8%, 
respectively. Almost all bacteria, with exception of A.baumanii, causing UTIs in our patients 
were sensitive do carbapenems. 
 
CONCLUSIONS: Diabetes mellitus was the most common predisposing factor in our patients. 
With a number over 60% the most common pathogen was E.coli, far behind it in second place 
was P.aureginosa with only 10.2%. Over 90% of E.coli isolates were sensitive to amoxicillin-
clavulanic acid which makes this antibiotic a reliable first choice as an empirical treatment for 
community acquired UTIs.Trimethoprim-sulfamethoxazole, fluoroquinolone and to a certain 
degree cephalosporins should not be used before the antibiotic susceptibility of the pathogen is 
known. Carbapenems are a reliable first choice of antibiotics. 
 
 
 
 
42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9. CROATIAN SUMMARY 
43 
 
Naslov: Infekcije mokraćnog sustava liječene na Klinici za infektologiju Kliničkog 
bolničkog centra Split u razdoblju od 2016.-2017. godine: epidemiološke, 
kliničke i mikrobiološke osobine. 
 
Ciljevi: utvrditi predispozicijske čimbenike, najčešće uzročnike i njihovu osjetljivost na 
antibiotike u bolesnika s infekcijama mokraćnog sustava (IMS). 
 
Materijali i metode: Studija je obuhvatila 175 bolesnika s dijagnozom cistitisa, pijelonefitisa 
i prostatitisa bez dokazane bakterijemije koji su liječeni na Klinici za infektologiju kliničkog 
bolničkog centra Split u razdoblju od 2016.-2017.godine. Svim bolesnicima je dijagnoza 
postavljena temeljem kliničke procjene i laboratorijske dijagnostike. Medicinski podaci su 
prikupljeni pregledom povijesti bolesti iz arhive Klinike za infektologiju.  
 
Rezultati: Najviše bolesnika (27,4%) bio je u dobnoj skupni od 80 i više godina. Većina 
bolesnika bile su žene (61,1%). Gotovo polovica naših bolesnika (48,9%) imala je jedan ili više 
predispozicijskih čimbenika za infekciju mokraćnog sustava. Najzastupljenije predispozicije su 
bile diabetes mellitus (14,9%), različita neurološka stanja koja su povezana s inkontinencijom 
ili retencijom urina (13,7%) i trajni urinski kateter (7,4%). E.coli bila je daleko najčešći 
uzročnik IMS (62,8%), na drugom mjestu P.aureginosa (10,2%), a potom slijede P.mirabilis 
(8,2%) i Klebsiella (5,6%). Gotovo polovica izoliranih E.coli (48,0%) bilo je rezistentno na 
ampicilin, a samo 7,3% ih je bilo rezistentno na amoksicilin-klavulanat, dok ih je na 
trimetoprim-sulfametoksazol i flurokinolone bilo rezistetno 29,3% , odnosno 22,8%. Gotovo 
sve bakterije, s izuzetkom A. bauumanii, koje su uzrokovale IMS u naših bolesnka bile su 
osjetljive na karbapeneme. 
 
Zaključci: Dijabetes melitus je najčešći predispozcijski faktor IMSa u naših bolesnika. S 
udjelom od preko 60% najčešći uzročnik bio je E.coli , a daleko iza nje na drugom mjestu je 
P.aeruginosa s tek 10,2% . Preko 90% izolata E.coli bilo je osjetljivo na amksicilin-klavulanat 
što čini ovaj antibiotik pouzdanih prvim izborom za empirijsko liječenje vanbolnički stečenih 
IMSa. Trimetoprim-sulfametoxazol, fluorokionolone, pa u određenom opsegu i cefalosporine 
ne bi trebalo primjenjivati prije nego je poznata antibiotska osjetljivost uzročnika. Karbapenemi 
su pouzdani antibiotici prvog izbora.  
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